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Background: Nanotechnologies are significant modern trend
embracing various fields of science including biology and medi-
cine. Investigations of biological activities of nanoparticles (NP)
suggest perspectives of their application in oncology. The role of
metals in metabolic processes in the organism is well known,
but a few data are available about the activities of nanometals.
Our aim was to study the effect of metallic nanoparticles on
growth of xenografts of human lung cancer and transplanted
mouse tumors.
Materials and methods: Nanoparticles (NP) are ultrasmall
metallic pulvers of Zn, Cu, Fe (size 40–100 nm). NP effects on
growth of xenografts of human lung carcinoma cultured in cham-
bers were studied in a following way. Samples of lung cancer
patients’ tumor were put into chambers made of plastic and fil-
ters with pores 230 nm size. Chambers were implanted into rats’
abdominal cavity and NP suspension was administered intraperi-
toneally 3 times during the incubation period (6 days). Control
animals were injected with 0.85% NaCl solution. After incubation
filters were processed and stained for microscopy; amount of
injured cells was counted. The experimental study of the NP
effect on growth of transplanted tumors was carried out in mice
with sarcomas (S37 and S180). NP suspensions were administered
paratumoraly in total dose 20 lg/mouse; control mice were
injected with 0.85% NaCl solution. Dynamics of tumor growth
(S37, S180), tumor histology and cytology (S37), survival and life-
span of mice (S180) were assessed.
Results: The results of histologic study of lung cancer tissue
grown in chambers during 6 days showed vast injury of tumor
cells, the most significant after administration of NP Cu. The
amount of damaged cells was 93.4 ± 1.09% after NP Cu injection,
66.3 ± 2.28% after NP Zn injection, 37.6 ± 1.82% after NP Fe injec-
tion and only 18.3 ± 0.87% in control samples. The effect was
independent of the tumors’ histostructure (adenocarcinoma,
squamous cell carcinoma). Injection of metallic NP to tumor-
bearing mice caused tumor regression both of S37 and S180. It
was followed by death or severe destruction of S37 cells in ascitic
and solid components of the tumor, maximal damage seen after
application of NP Zn, minimal one after use of NP Fe. Volume of
ascitic fluid in control mice with S 37 was 1.8 ± 0.66 ml with
(27.7 ± 2.86)  106/ml of alive tumor cells; after administration of
NP Zn the parameters were only 0.78 ± 0.3 ml and (1.67 ± 0.5) 
106/ml respectively (P < 0.05). Volume of solid tumor was (574
± 95) mm3 in control animals while in mice receiving NP Zn it
reached only(154 ± 88) mm3 (P < 0.05).
Results of histologic study of S37 showed that injection of NP
Zn and NP Cu caused advanced increase of damaged tumor cells’
percentage (71.7 ± 8.7% and 48.2 ± 5.6%, respectively vs 13.7 ± 2.3%
in control group). NP Fe induced destruction of 21.7 ± 4.3% of S37
cells.
Tumor regression up to complete one was found also
in S 180-bearing mice, as well as 3-4-fold prolongation of animals’
life-span without any visible signs of toxicity after injection of all
studied kinds of NP.
Conclusion: Doubtless antitumor effect of metallic NP was
demonstrated on various experimental models of tumor growth
including human and animal malignant tumors. NP caused injury
of lung cancer cells cultured in chambers. Local injection of
metallic NP induced death and/or destruction of tumor cells,
decrease of tumor volume, inhibition of tumor growth and signif-
icant prolongation of experimental animals’ life span. Effect of NP
Zn was found to be the strongest in vivo while NP Cu showed the
most cytotoxic effect on lung carcinoma xenografts.
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Background: Mesenchymal stem cells or multipotent mes-
enchymal stromal cells (MSCs) are multipotent progenitor cells
used to function as cellular delivery vehicles for antitumor agents
(Miletic et al., 2007; Gunnarsson et al., 2010; van Eekelen et al.,
2010; Studeny et al., 2002). The use of mesenchymal stem cells
for the delivery of anticancer drugs based on the hypothesis that
stem cells migrate predominantly into tumor tissue. However, the
property of MSCs migrate to the tumor is not clear demonstrated
and requires further experimental confirmation. The aim of our
study is to identify how tumor growth affects on MSCs distribu-
tion after systemic administration on a model melanoma B16F10.
Materials and methods: There were two groups of mice in this
study: healthy + intravenously transplantation MSCs (n = 5),
B16F10 + intravenously transplantation MSCs (3 days later tumor
inoculation) (n = 5). Preparation of MSCs for transplantation: the
isolation of MSCs from bone marrow of male C57BL/6 mice was
performed using the methods described in work of Esposito M.
(Bazan et al., 2004). To investigate their capacity for mesodermal
differentiation adipogenic and osteogenic differentiation was car-
ried out. To phenotype cell-surface antigens, MSCs were stained
with FITC, PE or APC-conjugated antibodies specific for the fol-
lowing mice antigens CD45-FITC, CD90-FITC, CD34-PE, CD73- PE,
and CD105-APC. Stained cells were analysed using FACS Calibur
flow cytometer (Becton Dickinson, USA).
One hour, 3, 7 and 14 days after cell transplantation (3, 7, 10,
17 days after tumor inoculation, respectively), the animals were
sacrified by cervical dislocation. The blood, tumor, lymph nodes,
sentinel lymph nodes (regional lymph nodes), lung, liver, spleen,
bone marrow, brain, heart from each animal were immediately
excised and processed for qPCR analysis. Fur further validatuion
of PCR measurements, fluorescence microscopy of a section of
bone marrow of mice bearing melanoma B16F10 was performed
to detect Hoechst 33342 labeled transplanted cells.
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Results: MSCs isolated from bone marrow possess ability to
differentiate into osteocytes and adipocytes, plastic adherence
and expression of cluster of differentiation (CD) markers such
as CD105, CD73, and CD90 in >95% of the culture with absent
expression of markers including CD34 and CD45. In order to study
the effect of the melanoma B16F10 growth on the distribution of
transplanted MSCs, we have shown the similarities and differ-
ences in the distribution of MSCs in the body of healthy animals
and animal bearing tumor. 50–65% of Y-positive MSCs detected in
lungs as healthy mice, as mice bearing melanoma B16F10 after
one hour of MSCs administrated. We found Hoechst labeled MSCs
in capillaries of interalveolar septa by fluorescent microscopy. In
other examined organs, Y-positive cells were not found. Tumor
tissue contained the maximum number of transplanted MSCs 3
days after cell transplantation. In 3 days after MSCs administra-
tion heart and brain of mice bearing melanoma B16F10 contained
significantly greater number of Y-positive cells compared to those
of healthy mice. In 7 and 14 days after transplantation, bone mar-
row of mice bearing tumor contained more than 2000 Y-positive
cells/100,000, while in the bone marrow of healthy animals,
onlysingle cellswere detected.
Conclusion: Melanoma B16F10 affects on pattern of mesenchy-
mal stem cell distribution, which depends on stage of tumor
growth.
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